Quantcast
Last updated on April 18, 2014 at 5:30 EDT

Latest Pfenex Inc. Stories

2013-12-17 08:30:18

SAN DIEGO, Dec. 17, 2013 /PRNewswire/ -- Pfenex Inc. today announced that Leidos Holdings, Inc. (NYSE: LDOS) (formerly SAIC) has awarded Pfenex a subcontract in support of the development of an anthrax vaccine containing its recombinant protective antigen (rPA) and a novel, immune-enhancing adjuvant. The prime contract was awarded to Leidos by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to improve the efficacy of...

2013-11-05 08:36:07

SAN DIEGO, Nov. 5, 2013 /PRNewswire/ -- Pfenex Inc. today announced that it has awarded Paragon Bioservices a contract for the current Good Manufacturing Practice (cGMP) manufacturing of its rPA based anthrax vaccine. Paragon Bioservices will implement the cGMP-ready Pfenex Expression Technology(TM)-based production process that has been developed at Pfenex, through its vaccines division. Funding will be provided by the Department of Health and Human Services (HHS), through the...

2013-10-29 08:33:54

Funding will be provided by Leidos through its Malaria Vaccine Production and Support Services Contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health SAN DIEGO, Oct. 29, 2013 /PRNewswire/ -- Pfenex Inc. today announced that Leidos Holdings, Inc. (NYSE: LDOS) (formerly SAIC) has awarded Pfenex a subcontract to develop a robust, scalable, cGMP-ready production process for large-scale production of the blood-stage...

2013-10-01 08:32:26

Funding will be provided by the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services. SAN DIEGO, Oct. 1, 2013 /PRNewswire/ -- Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has modified its prime contract and simultaneously exercised an...

2013-04-30 08:32:42

SAN DIEGO, Calif. and OXFORD, England, April 30, 2013 /PRNewswire/ -- Glide Pharma(®) today announced the award of a sub-contract from Pfenex Inc. to develop a solid formulation containing the recombinant Protective Antigen (rPA) from Bacillus anthracis expressed in Pfenex Expression Technology(TM) suitable for delivery with the Glide SDI(® )(solid dose injector). This approach will address two important logistical constraints of the currently available vaccine, namely, long...

2013-04-16 08:28:07

SAN DIEGO and BANGALORE, India, April 16, 2013 /PRNewswire/ -- Pfenex Inc. and Agila Biotech Private Limited, a subsidiary of Strides Arcolab Limited today announced that they have entered into a joint venture to develop, manufacture and commercialize an initial pipeline of six biosimilar products for the global market. Operating as a JV, wherein both parties will equally share in decision making regarding product development and commercialization, Agila Biotech will be a 51% equity...

2012-10-24 15:25:22

In the news release, Pfenex Inc. Awards Althea Technologies a Contract for cGMP Manufacturing of Circumsporozoite Protein from Plasmodium falciparum, a Key Malaria Antigen, issued 24-Oct-2012 by Pfenex Inc. over PR Newswire, we are advised by the company that in the third paragraph, the last sentence should have been a quote attributed to Dr. Annie Mo. This quote is now the fourth paragraph. The complete, corrected release follows: Pfenex Inc. Awards Althea Technologies a Contract for cGMP...

2012-10-24 07:30:36

SAN DIEGO, Oct. 24, 2012 /PRNewswire/ -- Pfenex Inc. today announced that it has awarded Althea Technologies a contract for the current Good Manufacturing Practice (cGMP) manufacturing of circumsporozoite protein (CSP) from Plasmodium falciparum, an important and proven component of an effective malaria vaccine. Althea Technologies will implement the cGMP-ready Pf?nex Expression Technology(TM)-based production process that was developed at Pfenex over the past several months. Processes for...

2012-10-17 07:27:45

SAN DIEGO, Oct. 17, 2012 /PRNewswire/ -- Pfenex Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID) under its Broad Agency Announcement entitled "Vaccine Technologies to Advance Next Generation Anthrax Vaccines" (BAA-NIAID-DMID-NIHAI2010104) has awarded Pfenex a contract to develop an alternative delivery method for Pfenex's recombinant Protective Antigen (rPA)-based anthrax vaccine. NIAID, part of the National Institutes of Health, has made an initial...

2012-06-05 06:28:27

SAN DIEGO, June 5, 2012 /PRNewswire/ -- Based on its comprehensive TEAM Research(TM) rigorous 10 step evaluation methodology, Frost & Sullivan has awarded Pfenex Inc. with the 2012 North American Enabling Technology Award in Microbial Expression Technology. Frost & Sullivan industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry. In order to be...